# A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma

> **NCT04763408** · — · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 335 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT04763408
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-09
- **Primary completion:** 2023-12-13
- **Final completion:** 2023-12-13
- **Target enrollment:** 335 (ACTUAL)
- **Last updated:** 2024-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04763408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04763408, "A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04763408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*